Category Archives: Biotech Stocks

Small-Cap Stock Performers: Progressive Care’s RXMD Still Leading the Pack

Small-Cap Stock Performers: Progressive Care’s RXMD Still Leading the Pack

As the broader market starts to show evidence of topping-out, many investors have switched to small-cap alternatives are a potential driver of portfolio growth.

One of the names that continues to stand out from the pack is South Florida healthcare services and technology company Progressive Care, Inc. (OTCMKTS: RXMD), which has attracted a great deal of attention after the stock saw a price spike of 1,150% in the the period spanning from February to March. Valuations jumped from $0.02 in January to $0.25 in March 2018 – and this has helped the stock’s post rallies of 250% year-to-date.

It almost goes without saying but this means that RXMD has strongly outperformed the market (as the S&P 500 is showing gains of only 2% for this year). But can these impressive trends continue? Here, we will look at some of the factors driving growth for Progressive Care and its businesses.

RXMD Stock Performance Overview

One of the central reasons RXMD stock has gained so much attention (and its increase in trading volume) has been the rise in prescriptions filled during the first-quarter of this year. For the period, Progressive Care reported an increase of 24% in prescriptions filled (on an annualized basis). In February alone, the company filled $470,000 in prescriptions and generated fees of $20,000 (which was a 200% gain relative to the year-ago figure). These are stellar gains, no matter how you view the numbers.

RXMD Healthcare stock
RXMD Healthcare stock
However, in April 2018, shares came tumbling down, losing 65% (to $0.08) on security concerns related to Progressive’s website. This event, along with speculation of insider selling by its funding partner Chicago Venture Partners put the stock back near pre-breakout levels. But share prices have stabilized after both concerns were addressed by Progressive Care CEO S. Parikh Mars via an open to letter to the shareholders (which confronted the negative reports). RXMD rebounded after the announcements were made.

RXMD Financial Outlook

RXMD performed well during the quarter ending March 31st, 2018. Revenues came in at $1.9 million (which was the largest revenue generation in any single month in the company’s history). Net revenues of $5 million were an increase of 7.36% from the year-ago period. Overall, the revenue figures have jumped from $9 million in 2013 to $20 million in 2017. This is an impressive performance for a company with only 50 employees.

RXMD filled in 64,000 prescriptions in Q1 2018, and the company’s total assets have increased by 49% relative to Q1 2017. Operating cash flow went from $-8,641 to a whopping $309,827 (+3,000%) for the period. These numbers have created a healthy balance sheet – and this shows the stock is set to bring in massive yields for its shareholders.

Progressive Care is currently licensed in 10 states, with more licenses currently in progress. This is clear evidence that the company is continuing to build its brand and build on its prior accomplishments. In December 2017, RXMD was listed on the OTCQB – and there is scope for the stock to be listed on the NASDAQ in the future. With its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, RXMD now stands strong with its four central pillars:

  • Expertise in healthcare
  • Patient care
  • Pharmaceutical management
  • Customer service

The recent quarter was a momentous period due to the following achievements:

  • Introduction of Bitcoin to its payment platform
  • Record-breaking numbers in terms of its financial strength
  • Plans made to acquire Touchpoint RX pharmacy in Palm Beach County
  • Price target upgraded to $0.35 per share by the investor analyst SeeThruEquity

For 2018, RXMD has set a revenue goal of $22 million along with monthly prescription numbers of 25,000. With its current market capitalization of $35 million and a substantial cash balance, RXMD is set to become a favored growth stock for prudent investors.

Rising Industry Sectors

For investors looking to gain entry into the rising healthcare industry, it looks likely that Progressive Care’s RXMD will continue leading the pack. The level of momentum that has been present in the stock is rare, as there are not many industry sectors that can reasonably expect to grow more than 300% in the next few years.  

Great potential for growth in this sector comes from the fact that regulatory approval processes has been streamlined over the last few years. Many states are considering taking things in this direction, and this has made sales predictions increasingly optimistic for the company. Throughout the sector as a whole, RXMD remains attractive given its growth prospects and recent pullback to pre-breakout levels. For these reasons, the stock looks likely to gain on its bullish momentum in the months ahead.

Biotech Companies: Breast Cancer and Market Trends

Biotech Companies: Breast Cancer and Market Trends

Stock investors looking for a cross between biotech and cryptocurrencies might have just found their answer.  Rising medical costs and insufficient record-keeping for patients suggests that blockchain technology is ripe for consumer growth.

The world needs biotech companies that implement blockchain technology.  This is why cancer researchers changed directions.  Cancer trends are on the rise in the U.S. (and throughout the world), as an aging population continually requires more healthcare services and pharmaceutical costs.  Disruptive market forces are needed in the improvement of patients in cancer care.  It is important for consumers to join together in digital communities educate one another about these devastating illnesses, so that we can better understand the costs for ourselves and for our families.

Breast cancer: What you need to know about it

As its name suggests, breast cancer is a type of cancer that affects the tissues of the breasts – specifically in the milk-producing ducts. According to the statistics, breast cancer is the most common type of cancer affecting women worldwide, accounting for more than 25% of all cancers diagnosed. In the US alone, it is expected that about 12% (or 1 in 8 women) will acquire cancer throughout their lifetimes.

Breast Cancer Stats
Breast Cancer Stats

This year, more than 260,000 cases of breast cancer are expected to be diagnosed in women in the United States (In males, only about 2,500 cases are estimated). With breast cancer becoming more common especially in developing countries, it is important to be updated with the correct information about it as well as with the latest treatment methods. Listed below are some of the most important things you should know about this cancer type.

The risk factors

Basically, there are three main risk factors in the development of breast cancer: age, sex, and family history. According to studies, the incidence of breast cancer increases as a person gets older. On the other hand, factors like sex and family history are beyond one’s control.

Studies show that breast cancer is more prevalent in women than in men, and is more common in people who (may) have inherited the disease. On the molecular level, breast cancer is caused by any changes in genes like BRCA1 and BRCA2. Since these mutations occur in the genes, they can be passed on from one generation to another.

Aside from these aforementioned, factors such as diet and physical activity can also cause breast cancer. But unlike the first three factors, they can be controlled and regulated.

Myths and misconceptions

Breast cancer is often thought to be a single disease.  But, in fact, there are many types and subtypes.  These include estrogen-positive, triple-negative, HER2-positive, invasive and non-invasive, among others.

Breast Cancer Stats
Breast Cancer Stats

Another common misconception about breast cancer is that it only affects women. While the risk factors are relatively lower, men can also acquire breast cancer and die from it. However, since most men do not often suspect breast cancer during its early stages, the treatment methods are usually done only in severe cases.

Latest diagnosis and treatment methods

Like any other disease, the key to treating breast cancer is its early detection. It has already been scientifically proven that early diagnosis of the disease can lead to less destructive treatment and overall improvement in survival. One of the most common ways to diagnose breast cancer is through the use of mammograms.

According to studies, the use of mammograms reduces deaths from breast cancer by about 20%. Because of this, experts still suggest the yearly schedule of mammograms for women who are age-40 and above.

Cancer Warning Signs
Cancer Warning Signs

In past years, there has been a lot of new treatment methods developed against different breast cancer types. Some of the most common methods include surgery (known as mastectomy), chemotherapy, radiation therapy, and hormone therapy.

Aside from these, drugs such as Nerlynx, a tyrosine-kinase inhibitor, has already been approved by the FDA to be used as a treatment for the early stage of HER2-positive breast cancer.

Blockchain-Based Technologies

Recent developments in blockchain technologies have highlighted social health platforms which have already helped patients make progress in many of these areas.

Under the Obama administration, there was a large focus on healthcare reform.  There is a wide chasm of debate on how successful those initiatives were, but this could become a central issue in the next election (given the fact that relatively little healthcare legislation has been passed under the Trump administration).  More realistically, improvements in healthcare will need to come from the private sector through the use of innovative technologies.

Digital health communities can enable better records management, reduce costs, and improve the lives of patients.  Working together, we can move forward in the fight against cancer.  Markets will continue monitoring these areas and industries, as there will continue to be impressive growth to be seen here in the years and decades ahead.